Invention Grant
- Patent Title: Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
-
Application No.: US15918343Application Date: 2018-03-12
-
Publication No.: US10239934B2Publication Date: 2019-03-26
- Inventor: Po-Ying Chan-Hui , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Marjorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos , Stephen Kaminsky
- Applicant: Theraclone Sciences, Inc. , International AIDS Vaccine Initiative , The Scripps Research Institute
- Applicant Address: US WA Seattle US NY New York US CA La Jolla
- Assignee: Theraclone Sciences, Inc.,International AIDS Vaccine Initiative,The Scripps Research Institute
- Current Assignee: Theraclone Sciences, Inc.,International AIDS Vaccine Initiative,The Scripps Research Institute
- Current Assignee Address: US WA Seattle US NY New York US CA La Jolla
- Agency: Duane Morris LLP
- Agent Thomas J. Kowalski; Deborah L. Lu
- Main IPC: C07K16/10
- IPC: C07K16/10 ; A61K39/00 ; A61K39/21 ; C07K16/08 ; A61K38/00

Abstract:
The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
Public/Granted literature
Information query